Startups
T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, currently in Phase 2 clinical trials, as a potential disease-modifying medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 for the treatment of other neurodegenerative diseases, including Huntington’s disease.
T3D-959 is designed as an orally-delivered, once-a-day medicine being evaluated for the treatment of Alzheimer’s disease patients with mild to moderate disease severity. The mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) or neurodegenerative disorders via improving dysfunctional brain glucose energy and lipid metabolism which in turn, can address cerebral structural (e.g. plaques and tangles) and stress event (e.g. inflammation, oxidative stress) aberrations.
T3D-959 is designed as an orally-delivered, once-a-day medicine being evaluated for the treatment of Alzheimer’s disease patients with mild to moderate disease severity. The mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) or neurodegenerative disorders via improving dysfunctional brain glucose energy and lipid metabolism which in turn, can address cerebral structural (e.g. plaques and tangles) and stress event (e.g. inflammation, oxidative stress) aberrations.
Overview
Location
United States, North Carolina
Phone
+1 919-237-4897
Total raised
$15M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 4, 2019 | T3D Therapeutics Raises $15M in Funding | T3D Therapeutics, a Research Triangle Park, NC-based clinical stage drug development company, closed on a $15m financing. A cornerstone investor provided the funds along with support from the National Institute on Aging (NIA), part of NIH. ... |
| Jan 13, 2018 | RTP-based T3D Therapeutics Raises Over $700,000 | A Research Triangle Park, North Carolina-based pharmaceutical company raised $711,270 in a combination of debt and options, according to a Securities and Exchange Commission filing. T3D Therapeutics Inc. filed the Form D on Friday. It state... |
| Jan 13, 2018 | RTP-based T3D Therapeutics Raises Over $700,000 | A Research Triangle Park, North Carolina-based pharmaceutical company raised $711,270 in a combination of debt and options, according to a Securities and Exchange Commission filing. T3D Therapeutics Inc. filed the Form D on Friday. It state... |
| Mar 24, 2015 | T3D Therapeutics’ drug explores the link between diabetes and Alzheimer’s disease | T3D just received a $1.8 million federal grant to get its experimental Alzheimer’s disease therapy on its legs. It’s otherwise raised another $1.8 million from angel investors since its 2013 launch, and will need about $1 million more in th... |
| Aug 12, 2013 | Pharma company developing Alzheimer’s pill that targets link between blood sugar and brain health | The Durham, North Carolina company licensed its technology from specialty pharmaceutical company DARA BioSciences, where Didsbury formerly served as president and chief operating officer. DARA had developed the drug candidate, now called T3... |
| Pharma company developing Alzheimer’s pill that targets link between blood sugar and brain health | A handful of high-profile Alzheimer’s disease drugs have failed in late-stage clinical trials in the last year — at least two of them based on the hypothesis that buildup of amyloid plaques in the brain give rise to neurodegeneration. Start... | |
| T3D Therapeutics’ drug explores the link between diabetes and Alzheimer’s disease | There’s a growing consensus that two of society’s most rampant public health issues – Type II Diabetes and Alzheimer’s disease – are intertwined. It’s not all about clearing plaques anymore: Insulin modulation is askew in both diseases, whi... |
Reviews 0
FAQ about T3D Therapeutics, Inc.
How much funding has T3D Therapeutics, Inc. raised?
T3D Therapeutics, Inc. has raised $15M in total across 1 funding round.
What has the press written about T3D Therapeutics, Inc.?
Parsers VC has collected 8 articles mentioning T3D Therapeutics, Inc., among them “T3D Therapeutics Raises $15M in Funding” (Nov 4, 2019) and “RTP-based T3D Therapeutics Raises Over $700,000” (Jan 13, 2018).
Is T3D Therapeutics, Inc. still active?
Yes, T3D Therapeutics, Inc. is active; its latest activity on Parsers VC dates from Apr 20, 2021.